Clinical Trial Update: Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation [Phase 2, Phase 3]

View source ↗

Summary

This document provides an update on a Phase 2/3 trial comparing ATI-5923, a novel vitamin K antagonist, with warfarin for patients requiring chronic anticoagula…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Atrial Flutter
• Cardiomyopathy
• Myocardial Infarction
• Venous Thromboembolism

Drugs mentioned

• ATI-5923 (ATI-5923)
• Warfarin (warfarin)

Snippet

Sponsor: ARYx Therapeutics | Conditions: Atrial Fibrillation, Atrial Flutter | Phase 2, Phase 3 | Status: UNKNOWN